AIRTRIP
2016
Anakinra-Treatment of Recurrent Idiopathic Pericarditis
In 21 patients with colchicine-resistant, corticosteroid-dependent recurrent pericarditis, continued anakinra markedly reduced recurrent pericarditis after randomised withdrawal compared with a switch to placebo.
Result
- Absolute difference
- 71.8 points
- NNT
- 2
Absolute difference and NNT are derived from the event rates.
Also reported: Transient injection-site reactions in 95.2 %.
- Subtopic
- Recurrent pericarditis
- Design
- Double-blind randomised-withdrawal RCT after an open-label run-in
- Relevance
- Supporting: context rather than must-know.
- Cited in
- ESC 2025 Myo/Pericarditis
- Source
- Brucato A, Imazio M, Gattorno M, et al. JAMA. 2016;316(18):1906-1912.doi 10.1001/jama.2016.15826
Discussion & critique
Tiny, single-country, and the randomised-withdrawal design enriches for responders, so the effect size is almost certainly inflated. It was the first randomised proof that interleukin-1 blockade breaks the corticosteroid-dependency cycle.